Cargando…

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria

Introduction: Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has been shown to be useful for st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziai, D., Wagner, T., El Badaoui, A., Hitzel, A., Woillard, J.B., Melloni, B., Monteil, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	e-Med 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589951/ https://www.ncbi.nlm.nih.gov/pubmed/23466871 http://dx.doi.org/10.1102/1470-7330.2013.0008

Ejemplares similares

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST
por: Depardon, Edouard, et al.
Publicado: (2018)

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
por: Rendl, Gundula, et al.
Publicado: (2022)

Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
por: Lasnon, Charline, et al.
Publicado: (2017)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
por: Vogsen, Marianne, et al.
Publicado: (2021)

Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria
por: Devriese, Joke, et al.
Publicado: (2018)

Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020)

Quantitation of cancer treatment response by 2-[(18)F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
por: O, Joo Hyun, et al.
Publicado: (2021)

Appropriateness criteria of FDG PET/CT in oncology
por: Agrawal, Archi, et al.
Publicado: (2015)

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs
por: Wagner, T., et al.
Publicado: (2012)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article
por: Nakajo, Masatoyo, et al.
Publicado: (2021)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

The Role of (18)F-FDG PET/CT in Large-Vessel Vasculitis: Appropriateness of Current Classification Criteria?
por: Balink, H., et al.
Publicado: (2014)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy
por: Fledelius, Joan, et al.
Publicado: (2016)

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
por: Van Heertum, Ronald L, et al.
Publicado: (2017)

FDG-PET/CT in lymphoma
por: D'souza, Maria M, et al.
Publicado: (2013)

FDG-PET and PET/CT - Part II
por: Takalkar, Amol M, et al.
Publicado: (2008)

Performance of Deauville Criteria in ([18F])FDG-PET/CT Diagnostics of Giant Cell Arteritis
por: Siefert, Jeffrey, et al.
Publicado: (2023)

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
por: Al-Ibraheem, Akram, et al.
Publicado: (2022)

FDG PET/CT of COVID-19
por: Zou, Sijuan, et al.
Publicado: (2020)

FDG PET or PET/CT in Evaluation of Renal Angiomyolipoma
por: Lin, Chun-Yi, et al.
Publicado: (2013)

Predictive and prognostic value of FDG-PET
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2008)

Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients
por: Catalano, O A, et al.
Publicado: (2015)

Prognostic value of FDG PET/CT in head and neck squamous cell carcinomas
por: Dequanter, D, et al.
Publicado: (2015)

Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer
por: De Raffele, Emilio, et al.
Publicado: (2017)

Prognostic significance of preoperative (18)F-FDG PET/CT in uterine leiomyosarcoma
por: Park, Jeong-Yeol, et al.
Publicado: (2017)

Prognostic Value of FDG PET/CT in Patients with Nodal Peripheral T-Cell Lymphoma
por: Choi, Woo Hee, et al.
Publicado: (2023)

(11)C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to (18)F-FDG PET/CT and Prognostic Value
por: Morales-Lozano, Maria I., et al.
Publicado: (2022)

Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria
por: Isohashi, Kayako, et al.
Publicado: (2015)

Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging
por: Boellaard, Ronald, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5kt612lm8omkun5fh5u4klhk87